Sentinus LLC’s AYTU BioPharma AYTU Stock Holding History

Sentinus LLC’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,000	Closed	-$52K	–	606
2025 Q4	$52K	Buy	+20,000	New	+$44.9K	0.01%	536

Other funds holding AYTU

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

CAM

Crown Advisors Management Larkspur, California $151M AUM 73.11% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sentinus LLC's AYTU Position: Q1 2026 in Review

Sentinus LLC sold out of AYTU BioPharma (AYTU) in Q1 2026, closing a stake of 20,000 shares — an estimated $52K sold.

Sentinus LLC first reported a position in AYTU in Q4 2025 and held it in 1 quarter. The position peaked at $52K in Q4 2025. 37 funds tracked by Wall St. Rank hold AYTU as of Q1 2026.

Sentinus LLC reported no remaining AYTU BioPharma position as of Q1 2026 after selling out during the quarter.
Sentinus LLC sold 20,000 AYTU BioPharma shares in Q1 2026, an estimated $52K.
Sentinus LLC first reported a position in AYTU BioPharma in Q4 2025 and held it in 1 quarter.
Sentinus LLC's AYTU BioPharma position peaked at $52K in Q4 2025.
37 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2026.

Based on Sentinus LLC's 13F filing for Q1 2026, filed 6 May 2026.